Ramucirumab in second‑line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation.

Publisher: Spandidos Publications] Country of Publication: Greece NLM ID: 101531236 Publication Model: eCollection Cited Medium: Internet ISSN: 1792-1082 (Electronic) Linking ISSN: 17921074 NLM ISO Abbreviation: Oncol Lett Subsets: PubMed not MEDLINE

Original Publication: [Athens : Spandidos Publications]

The present study investigated the role of ramucirumab (RAM) in treating liver metastases (LMs) as a second-line or salvage treatment in patients with advanced CRC. Of the 36 patients, 21 (58%) received RAM plus folinic acid, fluorouracil and irinotecan (FOLFIRI) as second-line treatment, whereas 15 (42%) received it in a salvage setting. The median overall survival time was 23 months [95% confidence interval (CI), 12-34 months] for those in the second-line treatment group and 8 months (95% CI, 5-19 months) for those in the salvage treatment group. Of the 36 patients, 14 (39%) underwent surgical resection of LMs during chemotherapy. A total of 6 patients underwent surgical resection for LMs for the first time during second-line RAM plus FOLFIRI (RAM-LM); of the remaining 8 patients, 6 underwent resection of LMs during first-line bevacizumab (BEV)-based chemotherapy (BEV-LM). Immunohistochemical analysis of CD42b showed that the platelet aggregation score (CD42b score), which ranges from 0 (absence of deposition) to 3 (presence of linear deposition), tended to decrease with the increasing duration of treatment with both RAM and BEV. Although there was no significant difference in the mean duration of anti-VEGF antibody treatment between the BEV-LM and RAM-LM groups, the median CD42b score was higher in the RAM-LM group (median CD42b score, 3; range, 0-3) compared with that in the BEV-LM group (median CD42b score, 1; range, 0-3; P=0.01), suggesting that RAM induces a different degree of platelet aggregation in liver sinusoids compared to BEV.
Competing Interests: The authors declare that they have no competing interests.
(Copyright: © 2024 Kimura et al.)

Eur J Cancer. 2009 Jan;45(2):228-47. (PMID: 19097774)
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. (PMID: 38572751)
Ann Oncol. 2017 Aug 01;28(8):1713-1729. (PMID: 28407110)
Int J Mol Sci. 2016 Feb 06;17(2):224. (PMID: 26861310)
Lancet. 2013 Jan 26;381(9863):303-12. (PMID: 23177514)
Lancet Oncol. 2015 May;16(5):499-508. (PMID: 25877855)
Am J Cancer Res. 2021 Jul 15;11(7):3461-3474. (PMID: 34354855)
J Surg Res. 2015 Feb;193(2):693-703. (PMID: 25266603)
J Natl Cancer Inst. 2018 Aug 1;110(8):888-894. (PMID: 29346573)
Lancet. 2016 Jul 30;388(10043):518-29. (PMID: 26853587)
Lancet Oncol. 2014 Oct;15(11):1224-35. (PMID: 25240821)
Nature. 2012 Jul 18;487(7407):330-7. (PMID: 22810696)
JAMA Oncol. 2017 Feb 01;3(2):194-201. (PMID: 27722750)
Am J Clin Oncol. 1982 Dec;5(6):649-55. (PMID: 7165009)
Toxicology. 2021 Aug;460:152882. (PMID: 34352347)
Transl Cancer Res. 2020 Sep;9(9):5645-5654. (PMID: 35117928)
Future Oncol. 2010 Jul;6(7):1085-94. (PMID: 20624120)
Gastroenterology. 2014 Apr;146(4):914-28. (PMID: 24389305)
Ann Surg. 2006 Aug;244(2):254-9. (PMID: 16858188)
Int J Clin Oncol. 2019 May;24(5):508-515. (PMID: 30604155)
Lancet Oncol. 2015 Jul;16(7):859-70. (PMID: 26095784)
N Engl J Med. 2013 Sep 12;369(11):1023-34. (PMID: 24024839)
Cell Signal. 2007 Oct;19(10):2003-12. (PMID: 17658244)

Keywords: advanced colorectal cancer; liver metastases; platelet aggregation; ramucirumab

Date Created: 20240731 Latest Revision: 20240801

20240801

PMC11287105

10.3892/ol.2024.14572

39081965